Announcement on behalf of subsidiary, Obigen Pharma Inc., that BOD resolved the Term Sheet for licensing of OBI-858 in China

1.Date of occurrence of the event:2022/07/21 2.Counterparty to the contract or commitment:A pharmaceutical company in China 3.Relationship with the Company:None 4.Starting and ending dates (or rescission date) of the contract or commitment:None 5.Major content (not applicable where rescinded): The Board of Directors of Obigen Pharma Inc. has resolved to enter into the Term Sheet for […]

This article is password protected.

To view the content, please enter your password in the field below